91µÎµÎ

Updated: Sun, 10/06/2024 - 10:30

From Saturday, Oct. 5 through Monday, Oct. 7, the Downtown and Macdonald Campuses will be open only to 91µÎµÎ students, employees and essential visitors. Many classes will be held online. Remote work required where possible. See Campus Public Safety website for details.


Du samedi 5 octobre au lundi 7 octobre, le campus du centre-ville et le campus Macdonald ne seront accessibles qu’aux étudiants et aux membres du personnel de l’Université 91µÎµÎ, ainsi qu’aux visiteurs essentiels. De nombreux cours auront lieu en ligne. Le personnel devra travailler à distance, si possible. Voir le site Web de la Direction de la protection et de la prévention pour plus de détails.

Marco Leyton

Academic title(s): 

Professor

Contact Information
Email address: 
marco.leyton [at] mcgill.ca
Phone: 
514-398-5804
Fax number: 
514-398-4866
Address: 

RI-91µÎµÎ Health Centre
1033 Pine Avenue West
Montreal, Quebec
H3A 1A1

Degree(s): 

PhD

Biography: 

Dr. Leyton is a Professor in the Department of Psychiatry at 91µÎµÎ. The focus of his research is the neurobiology of drug self-administration, addiction, and addiction-related neuropsychiatric disorders. Most of these studies are conducted on people and benefit from (i) a clinical research unit where drugs can be administered under safe conditions, and (ii) functional neuroimaging facilities at the Montreal Neurological Institute (PET, MRI). Dr. Leyton’s research has been particularly interested in the following questions. First, what are the acute effects of abused substances in the human brain, particularly within the mesocorticolimbic dopamine pathways? Second, what is the behavioural significance of drug-induced dopamine release in humans? Third, can repeated drug use produce long-lasting effects in the human brain, for example, conditioning, sensitization, and cross-sensitization? And since individual differences in drug-induced behavioural and neurobiological responses can be identified, he is studying (i) factors that might account for these differences, and (ii) whether the differences might influence susceptibility to addiction and addiction-related co-morbid conditions.

Back to top